Rein Therapeutics RNTX Income Statement (2016-2026)

NASDAQ RNTX
$0.79 +0.07 (+9.57%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Rein Therapeutics Quarterly Income Statement

Periods 42 quarters
Latest Jun 2026

Rein Therapeutics reported net income of -$6.08M for the quarter ended Jun 2026. This income statement covers 42 quarters of results from Mar 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
4.53M4.53M4.54M4.54M4.54M4.54M4.54M4.54M4.54M4.89M8.30M21.63M21.67M17.94M22.01M23.05M25.14M27.55M28.04M67.08M
Operating items
Research & DevelopmentR&D
4.28M4.56M5.89M5.43M4.24M2.40M1.81M0.19M0.02M1.97M3.46M3.74M3.72M3.32M3.05M4.29M1.68M2.00M3.07M3.64M
Selling, General & AdministrativeSG&A
2.51M2.25M2.53M2.61M2.24M2.30M2.18M1.89M1.96M5.33M3.74M5.30M2.35M2.48M2.56M2.58M3.81M1.96M2.16M2.44M
Restructuring CostsRestructuring
1.02M-0.09M0.01M-0.01M
Other Operating ExpensesOther Opex
37.00M28.70M
Operating ExpensesOpex
6.79M6.82M8.42M8.04M6.48M4.70M5.01M1.99M1.98M7.29M7.21M9.04M6.07M42.80M5.61M6.87M5.49M32.66M5.23M6.08M
Operating IncomeOp. Inc
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
EBIT
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Non-operating items
Non Operating Investment Income
Interest & Investment IncomeInt & Inv Inc
Other Non Operating IncomeOther Non Op Inc.
0.07M0.07M-0.02M0.00M0.34M0.23M0.20M0.16M-0.05M0.09M0.10M0.22M0.27M0.11M0.06M-0.09M-0.02M-0.61M0.46M
Net income details
EBT
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Profit After TaxPAT
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Income from Continuing OperationsIncome (Continuing)
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Consolidated Net IncomeConsol Net Inc.
-6.79M-6.82M-8.42M-8.04M-6.48M-4.70M-5.01M-1.99M-1.98M-7.29M-7.21M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M-5.23M-6.08M
Income towards Parent CompanyParent Net Inc
-6.70M-6.80M-8.42M-7.99M-6.37M-4.55M-4.78M-1.79M-1.83M-7.34M-7.11M-8.94M-5.85M-40.98M-5.50M-6.82M-5.58M-31.97M-5.84M-6.38M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-6.70M-6.80M-8.42M-7.99M-6.37M-4.55M-4.78M-1.79M-1.83M-7.34M-7.11M-8.94M-5.85M-40.98M-5.50M-6.82M-5.58M-31.97M-5.84M-6.38M
Additional items
EPS (Basic)
-1.48-1.53-1.86-1.76-1.40-1.00-1.05-0.39-0.40-1.60-0.86-0.45-0.27-2.28-0.25-0.28-0.21-1.26-0.19-0.10
EPS (Diluted)
-1.48-1.53-1.86-1.76-1.40-1.00-1.05-0.39-0.40-1.60-0.86-0.45-0.27-2.28-0.25-0.28-0.21-1.26-0.19-0.10
Shares Outstanding
4.53M4.44M4.53M4.54M4.54M4.54M4.54M4.54M4.54M4.60M8.30M19.91M21.66M17.94M21.92M24.19M26.36M25.44M30.35M67.08M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
4.53M4.44M4.53M4.54M4.54M4.54M4.54M4.54M4.54M4.60M8.30M19.91M21.66M17.94M21.92M24.19M26.36M25.44M30.35M67.08M
EBITDA
-6.75M-6.78M-8.38M-8.00M-6.44M-4.66M-4.97M-1.98M-1.97M-7.24M-7.15M-9.04M-6.07M-42.80M-5.61M-6.87M-5.49M-32.66M

Rein Therapeutics Income Statement API

Pull Rein Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=RNTX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY